Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CoMentis
• Treatments: Bevacizumab; Mecamylamine

Criteria

Inclusion Criteria:

• > 55 years of age

• clinical diagnosis of neovascular AMD

Exclusion Criteria:

• confounding ocular condition